Video & Transcript Research : 'pharmaceuticals'

Page 1 of 48
TX
TX

Texas 89th 2nd C.S.

Health and Human Services Apr 2nd, 2025

Health & Human Services

TX
TX

Texas 89th Regular

Health and Human Services Apr 2nd, 2025

Health & Human Services

MN
MN

Minnesota 2025-2026 Regular Session

House Health Finance and Policy Committee 3/9/26

Health Finance and Policy

Transcript Highlights:
  • We cannot wait for an FDA-approved pharmaceutical version of a treatment that readily exists in nature
  • Board of Pharmacy adopted and enforces USP Chapter 795, which pertains to the compounding of pharmaceutical
  • Compounding refers to creating a pharmaceutical or changing a conventionally manufactured product.
Bills: HF3454, HF3917, HF2906, HF3832, HF3769
Keywords: social work, licensure, employment titles, health occupations, professional standards, medication repository, drug donation, healthcare, Minnesota Statutes, pharmacy, public health, controlled substances, psilocybin, psilocin, psychedelic, psychedelic medicine, hallucinogen, mushrooms, magic mushrooms, therapeutic use
US
US

US Federal 2025-2026 Regular Session

Business meeting to consider S.527, to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, S.1040, to amend the Federal Trade Commis Apr 3rd, 2025 at 09:15 am

Senate Judiciary

Transcript Highlights:
  • information sharing between the FDA and the Patent Office for joint work on patent matters, including pharmaceutical
  • One of the reasons is that big pharmaceutical companies, big pharma, are able to game the patent system
  • But pharmaceutical companies abuse and manipulate the patent system to block generics from coming to
  • I think we all know that generics biosimilars have to be safe, but for too long the pharmaceutical companies
Bills: SB1040, SB1041, SB1095, SB1096, SB1097, SB527
Keywords: drug competition, product hopping, generic drugs, biosimilars, federal regulations, FTC Act, patent, biological products, healthcare access, affordable prescriptions, Medicare, Federal Trade Commission, sham petitions, competition, public health, unfair competition, healthcare, pharmaceutical, antitrust law, pay-for-delay
Summary: The meeting focused on addressing the high cost of prescription drugs and the abusive practices that contribute to elevated prices affecting American families. Several bills were presented, including proposals to end pay-for-delay deals and to enhance transparency in the operations of pharmacy benefit managers (PBMs). The discussion was notable for its emphasis on consumer protection and ensuring that cheaper generic drugs reach the market more effectively. Members expressed frustration over past attempts to pass similar legislation stalling in the Senate, leading to renewed efforts to push these bills forward.
TX
TX

Texas 89th Regular

Senate Committee on Health and Human Services Apr 2nd, 2025

Health & Human Services

TX
TX

Texas 89th Regular

Health and Human Services (Part II) May 21st, 2025

Health & Human Services

TX
TX

Texas 89th Regular

Health and Human Services (Part I) May 21st, 2025

Health & Human Services

TX
TX

Texas 89th Regular

Senate Committee on Health and Human Services (Part II) May 21st, 2025

Health & Human Services

Transcript Highlights:
  • Members, last session I sponsored House Bill 1490, which created the Texas Pharmaceutical Initiative
  • Members, the Texas Pharmaceutical Initiative is really an answer to trying to cut costs.
Bills: HB1106, HB3284, HB541, HB713, HB1403, HB1586, HB1942, HB2070, HB2844, HB2851, HB3151, HB3749, HB3940, HB3963, HB4454, HB4466, HB4795, HB5154, HB5394, SB1357, HB1052, HB4099, HB4638, HB5147
Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health
TX
TX

Texas 89th Regular

Senate Committee on Health and Human Services (Part I) May 21st, 2025

Health & Human Services

Transcript Highlights:
  • that it gets tagged as a drug, but it's just another indication of the stranglehold that the pharmaceutical
  • companies have on... ...the FDA and what's allowed out there because this is not something where the pharmaceutical
Bills: HB1106, HB3284, HB541, HB713, HB1403, HB1586, HB1942, HB2070, HB2844, HB2851, HB3151, HB3749, HB3940, HB3963, HB4454, HB4466, HB4795, HB5154, HB5394, SB1357, HB1052, HB4099, HB4638, HB5147
Keywords: child abuse, neglect, gender identity, sexual orientation, child welfare, marriage, family, Texas Commission, family welfare, marriage support, stability, premarital education, child development, strong families, direct patient care, healthcare, physicians, medical services, insurance regulation, maternal health
LA
LA

Louisiana 2026 Regular Session

Health and Welfare Apr 1st, 2026

Health and Welfare

TX
TX

Texas 89th Regular

Public Health Apr 21st, 2025

Public Health

Transcript Highlights:
  • members, I appreciate the opportunity to lay out House Bill 4638. which relates to the Texas Pharmaceutical
  • enough to remember when that changed, when you started to see some of these marriages between pharmaceutical
  • So imagine for an indication that's not specifically indicated by the FDA, in this case a pharmaceutical
Bills: HB5141, HB4638, HB2264, HB2035, HB4813, HB4408, HB2684, HB1621, HB2300, HB216, HB3829, HB4466, HB1747, HB2284, HB3614, HB2587, HB3219, HB3318, HB5147, HB4014, HB216
Keywords: lease, state property, public purpose, Travis County, Health and Human Services, pharmaceutical initiative, drug distribution, healthcare services, generic drugs, advanced pharmaceuticals, cost savings, mental health, patient discharge, medical records, health care professionals, substance use, family involvement, chemical dependency, treatment facilities, minor admissions
NM
NM

New Mexico 2025 Regular Session

IC - Legislative Health and Human Services Jul 22nd, 2025

Legislative Health & Human Services Committee

Transcript Highlights:
  • , it's Looking at every pharmaceutical, in particular new pharmaceuticals, involves assessing the value
  • And with pharmaceuticals, any kind of health care, but especially with pharmaceuticals, which are so
  • It's their pharmacies and pharmaceuticals.
  • Now it's pharmaceuticals.
  • And that's a combination of using a lot of pharmaceuticals and very, very expensive pharmaceuticals.
MA
MA

Massachusetts 2025-2026 Regular Session

Joint Committee on Health Care Financing Jun 21st, 2026 at 11:00 am

Joint Committee on Health Care Financing

Transcript Highlights:
  • I agree that it's very clear that we need to focus on pharmaceutical manufacturers, pharmaceutical benefit
  • That's far in excess of any pharmaceutical company, quite honestly.
  • A new Office of Pharmaceutical Policy and Analysis was created within HPC.
  • A new Office of Pharmaceutical Policy and Analysis was created within HPC.
  • So basically the pharmaceutical companies don't have leverage against the PBMs? Yeah.
Keywords: 995, all
Summary: The Joint Committee on Health Care Financing held a public hearing on a broad set of health care bills focused on cost, market oversight, pharmaceutical access, transparency, hospital closures, and pharmacy access. Chairs John Lawn and Cindy Friedman opened by emphasizing recent health care reforms and the need for further action on the drug supply chain, PBMs, private equity, and affordability. The committee heard testimony on several measures, including a Betsy Lehman Center bill to make technical changes and create a permanent trust account for federal and private funding, and bills on hospital profits and fairness, hospital closures and health planning, pharmacy deserts, and health care market oversight and pharmaceutical access. No votes were taken during the hearing. On the hospital profits bill, physicians and labor advocates strongly supported capping hospital CEO compensation at 50 times the lowest-paid worker, requiring greater financial transparency, and directing penalties from high-margin public hospitals into a Medicaid reimbursement fund. Testifiers argued that executive pay is excessive while frontline staff and safety-net services are under strain. Committee members raised concerns about unintended consequences, including whether hospitals might shift workers to contract status or lose executive talent, and whether the bill would actually direct money to the safety net. Supporters responded that the measure is one piece of a larger effort and that the bill’s Medicaid reimbursement provisions would help underserved hospitals. Testimony on market oversight and pharmaceutical access centered on rising health care and drug costs, PBM practices, and the proposal to give the Health Policy Commission authority to set upper payment limits for certain drugs. Consumer advocates, disability advocates, an independent pharmacist, the Attorney General’s office, and others supported stronger oversight, citing premium increases, affordability problems, and the impact of high drug prices on patients and community pharmacies. Pharma and some industry witnesses opposed parts of the bill, warning that upper payment limits could disrupt access, create legal issues, and fail to address the broader supply chain. The committee also heard support for stronger hospital closure notice and public hearing requirements, and for a pharmacy deserts bill aimed at identifying and addressing closures like the one in Roxbury that affected thousands of patients.
MN
MN

Minnesota 2025-2026 Regular Session

Press Conference: Lawmakers Speak on Enforcement For 340B Drug Pricing Plan Protections - 04/07/26

Transcript Highlights:
  • Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
  • Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
  • Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
  • Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
  • low-cost medications from pharmaceutical low-cost medications from pharmaceutical manufacturers<
Keywords: 918, senate, all
Summary: The meeting focused on a Minnesota Senate floor debate over a bipartisan 340B enforcement bill, with supporters arguing that the measure would require pharmaceutical companies to comply with federal and state law and continue providing discounted drugs to safety-net and rural hospitals. Senators and other speakers said the program is essential to hospital finances, especially for facilities facing operating losses and federal Medicaid cuts, and warned that without enforcement language hospitals such as Hennepin County Medical Center and rural hospitals could face severe financial harm or closure. Supporters also said pharmaceutical companies had spent heavily on media and lobbying to oppose the bill and that the Senate’s bipartisan vote showed the issue had broad support. Several speakers described how 340B revenue is used to sustain hospital services, including addiction treatment, trauma care, and other essential care in vulnerable communities. They said the program was designed to let hospitals buy drugs at low cost and bill insurers at standard rates, using the difference as a funding stream. When asked about claims that hospitals made large sums from the program, supporters said that was consistent with the program’s purpose. They also said some drug companies were not complying with 340B obligations, particularly around contract pharmacies, and that enforcement language was needed to ensure compliance. The discussion also addressed HCMC’s financial situation, with speakers saying 340B funding is not a full solution but is an important support and should not be reduced further. They rejected a proposed transparency/reporting amendment as too burdensome, while noting that federal authorities already have audit power over 340B dollars. The speakers urged the House to pass the same language, said eight Republicans joined the Senate vote, and expressed hope that the bill would advance despite concerns about House support and ongoing pharmaceutical industry opposition.
NM
NM

New Mexico 2025 Regular Session

IC - Legislative Health and Human Services Nov 5th, 2025

Legislative Health & Human Services Committee

Transcript Highlights:
  • Then we're going to, again, talk about Medicaid pharmaceutical costs.
  • But we do know that many of our pharmaceuticals and pharmaceutical components are imported.
  • We're seeing a substantial increase in pharmaceutical costs.
  • They're pharmaceutical cost strategies in the state of Oregon.
  • Pharmaceuticals are one of those.
NH
NH

New Hampshire 2025 Regular Session

Senate Health and Human Services (01/15/2025)

Health and Human Services

Transcript Highlights:
  • manufacturer a pharmaceutical manufacturer a pharmaceutical manufacturer<01:00:01.119> so
  • <01:01:25.160> company pharmaceutical company pharmaceutical company sitting<01:01:26.920>
  • <01:02:44.880> products coupons around pharmaceutical products coupons around pharmaceutical
  • Pharmaceuticals represent a significant part of the spend on health care provision, and the pharmaceutical
  • There were no pharmaceutical manufacturers there, but this bill is really about pharmaceutical manufacturer
Keywords: 1191, senate, all
KY
KY

Kentucky 2025 Regular Session

Senate Standing Committee on Health Services (2-5-25)

Transcript Highlights:
  • This expansion was done with the agreement of the pharmaceutical industry in order to have a place at
  • <00:08:40.680> industry agreement of the pharmaceutical industry agreement of the pharmaceutical
  • <00:26:28.279> iCal entirely supported by pharmaceutic iCal entirely supported by pharmaceutic
  • not one single pharmaceutical not one single pharmaceutical manufacturer<00:27:01.640> in
  • The pharmaceutical company agreed to that. For whatever reason, they were squeezed.
Keywords: 00:00 Introductions 02:46 Roll Call 03:35 Discussion on SB 14 46:13 Vote on SB 14 48:07 Discussion on SB 17 50:38 Vote on SB 17, 958, all
Summary: The Senate Standing Committee on Health Services opened with the chair welcoming several new members and outlining session rules: hearings would start and end on time, the committee would limit the number of bills heard each meeting, prioritize bills heard during the interim, and generally avoid using the consent calendar except in extreme circumstances. The committee then briefly considered administrative regulations, which were treated as approved if members had no questions. The main item was Senate Bill 14, a measure addressing the 340B drug discount program. The chair said the bill had already passed the Senate in a prior session and had been heard in interim, so he did not present it again. He described the bill as prohibiting drug manufacturers from discriminating against 340B covered entities by refusing 340B pricing when the same drug is offered at that price in the state. He also said the committee would not debate the federal 340B program itself, but would hear testimony on the bill. Hospital leaders and Kentucky Hospital Association representatives testified in support, arguing that 340B savings are essential to rural hospitals, oncology services, transportation support, chronic care, addiction recovery, and new service lines such as chemotherapy and hepatitis treatment. They said the program helps keep care close to home and that manufacturer restrictions on contract pharmacies have reduced access and cost hospitals millions. Opponents from BIO Kentucky and the National Alliance of Healthcare Purchaser Coalitions argued the bill would expand federal law beyond Congress’s intent, create administrative burdens, and not lower patient out-of-pocket costs. The chair repeatedly pressed opponents to address why Kentucky should be denied the same 340B pricing available in other states. No vote on the bill was taken in the portion provided.
MN
MN

Minnesota 2025-2026 Regular Session

FULL INTERVIEW: Patient-Centered Care | Senator John Marty Mar 20th, 2026

Minnesota Senate Floor Meeting

Transcript Highlights:
  • Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
  • Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
  • Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
  • Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
  • Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
Keywords: 918, senate, all
Summary: The interview focused on Senate File 3612, which the senator described as “patient-centered care” legislation for Minnesota’s Medicaid and MinnesotaCare programs. He said the bill would remove private insurers and HMOs from administering those public programs, replace them with a state contract for claims processing and administrative services, and shift care coordination directly to primary care clinics, counties, and nonprofits. He argued the current managed-care system creates churn, prior-authorization barriers, and fragmented care, and said providers should manage care rather than insurers. The senator repeatedly cited Connecticut as a model, saying that state moved away from managed care, improved primary care participation, and saved money. He also argued Minnesota’s current system lacks transparency and may be overpaying health plans, pointing to fraud concerns and a past example in which UCare returned money to the state after an overpayment. He said the bill would improve accountability, make fraud easier to detect, and could save taxpayers billions, though he emphasized his main goal was better care rather than savings. On support and prospects, he said the bill has backing from the governor and the American Cancer Society but currently only DFL co-authors. He said he does not expect it to become law this year because the fiscal note and details are still pending, and he does not expect insurance companies to support it. He added that he is open to discussion but sees the insurers as fundamentally opposed. The interview ended with him saying workers in insurance and claims processing should be treated fairly and offered retraining or dislocated-worker support if broader reforms reduce their roles.
MN
MN

Minnesota 2025-2026 Regular Session

Committee on Commerce and Consumer Protection - 03/03/26

Commerce and Consumer Protection

Transcript Highlights:
  • pharmaceuticals is spent on marketing. pharmaceuticals is spent on marketing.
  • <01:05:01.280> manufacturers<01:05:01.920> is pharmaceutical manufacturers is pharmaceutical
  • and the pharmaceut pharmacy and the pharmaceutical<01:20:11.840> industry.
  • Uh and that's pharmaceutical industry.
  • <01:27:18.880> industry that it puts the pharmaceutical industry that it puts the pharmaceutical
Keywords: 1187, senate, all
MA
MA

Massachusetts 2025-2026 Regular Session

Public Health Effects of Xylazine Jun 21st, 2026 at 02:00 pm

Transcript Highlights:
  • I don't know if we'll touch on this, but pharmaceutical-grade xylazine versus non-pharmaceutical-grade
  • compounds that you would attain from a pharmacy or from a pharmaceutical distributor or a compounding
  • The non-PG, as we call non-pharmaceutical-grade compounds.
  • It's a difference between, you know, pharmaceutical-grade approved versus, you know, what's out there
  • fentanyl and the non-pharmaceutical-grade fentanyl or the non-controlled production fentanyl.
Keywords: 995, all
Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.